These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6858779)

  • 1. The effect of lithium on the "on-off" phenomenon in parkinsonism.
    Coffey CE; Ross DR; Ferren EL; Bragdon AC; Hurwitz BJ; Olanow CW
    Adv Neurol; 1983; 37():61-73. PubMed ID: 6858779
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of the "on-off" phenomenon in Parkinsonism with lithium carbonate.
    Coffey CE; Ross DR; Ferren EL; Sullivan JL; Olanow CW
    Ann Neurol; 1982 Oct; 12(4):375-9. PubMed ID: 6816132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders.
    Timberlake WH
    Neurology; 1970 Dec; 20(12):31-5. PubMed ID: 4924342
    [No Abstract]   [Full Text] [Related]  

  • 4. Dyskinesias associated with lithium therapy in parkinsonism.
    Coffey CE; Ross DR; Massey EW; Olanow CW
    Clin Neuropharmacol; 1984; 7(3):223-9. PubMed ID: 6386151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levodopa and the "on-off" effect.
    Caine DB; Claveria LE; Allen JG
    Adv Neurol; 1974; 5():341-4. PubMed ID: 4440583
    [No Abstract]   [Full Text] [Related]  

  • 6. L-dopa, parkinsonism, and involuntary movements.
    Mayer RF
    Trans Am Neurol Assoc; 1974; 99():163-6. PubMed ID: 4463527
    [No Abstract]   [Full Text] [Related]  

  • 7. The "on-off" response to chronic L-DOPA treatment of Parkinsonism.
    Sweet RD; McDowell FH
    Adv Neurol; 1974; 5():331-8. PubMed ID: 4440581
    [No Abstract]   [Full Text] [Related]  

  • 8. Short- and long-term approaches to the "on-off" phenomenon.
    Papavasiliou PS; Cotzias GC; Mena I
    Adv Neurol; 1974; 5():379-86. PubMed ID: 4440585
    [No Abstract]   [Full Text] [Related]  

  • 9. The "on-off" side effect of L-DOPA.
    Markham CH
    Adv Neurol; 1974; 5():387-96. PubMed ID: 4440586
    [No Abstract]   [Full Text] [Related]  

  • 10. Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders.
    Timberlake WH
    Neurology; 1970 Dec; 20(12):Suppl:31-5. PubMed ID: 4921586
    [No Abstract]   [Full Text] [Related]  

  • 11. Variations in the "on-off" phenomenon.
    Duvoisin RC
    Adv Neurol; 1974; 5():339-40. PubMed ID: 4440582
    [No Abstract]   [Full Text] [Related]  

  • 12. Variations in the "on-off" effect.
    Yahr MD
    Adv Neurol; 1974; 5():397-9. PubMed ID: 4440587
    [No Abstract]   [Full Text] [Related]  

  • 13. The "on-off" effect.
    Carlsson A
    Adv Neurol; 1974; 5():367-8. PubMed ID: 4155235
    [No Abstract]   [Full Text] [Related]  

  • 14. [Levodopa and Parkinsonism. A double-blind study].
    Pakkenberg H; Dupont E; Garde B; Hansen E; Melsen S; Vestberg F
    Ugeskr Laeger; 1971 Nov; 133(46):2275-9. PubMed ID: 4944650
    [No Abstract]   [Full Text] [Related]  

  • 15. Nosological concept of juvenile parkinsonism with reference to the dopa-responsive syndrome.
    Yokochi M
    Adv Neurol; 1993; 60():548-52. PubMed ID: 8420189
    [No Abstract]   [Full Text] [Related]  

  • 16. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Levodopa as a single treatment of Parkinsonism. Long-term control of 24 cases with discrimination analysis].
    Borromei A; Manzini A
    Minerva Med; 1974 Nov; 65(79):4160-70. PubMed ID: 4610450
    [No Abstract]   [Full Text] [Related]  

  • 19. Parkinsonism, levodopa, and intelligence.
    Loranger A; Sweet RD; Goodell H; McDowell F
    Int J Neurol; 1975; 10(1-4):276-81. PubMed ID: 1181314
    [No Abstract]   [Full Text] [Related]  

  • 20. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
    Wolters EC; Horstink MW; Roos RA; Jansen EN
    Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.